NEW HAVEN, Conn., May 29, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc.
(NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing
novel antibiotics to treat serious bacterial infections, today announced that the underwriters of its
recently announced public offering of 22,000,000 shares of its common stock have exercised in
full their option purchase an additional 2,640,000 shares.